The adoption of Adoptive Cell Therapy Market has been increasing rapidly driven by the rising prevalence of cancer and increasing approvals of various adoptive cell therapy products. Adoptive cell therapy involves genetically modifying a patient's own immune cells to attack cancer cells. T cells isolated from patients are engineered to expressed receptors that make them recognize tumor antigens, which allow the cells to hunt and destroy cancer cells. Various types of cell therapies such as chimeric antigen receptor T-cell (CAR-T) therapy and tumor-infiltrating lymphocyte (TIL) therapy have been approved for the treatment of hematologic cancers. Furthermore, the number of ongoing clinical trials evaluating adoptive cell therapies for solid tumors has increased significantly over the past few years.

The Global Adoptive Cell Therapy Market is estimated to be valued at US$ 6,903.93 Mn in 2024 and is expected to exhibit a CAGR of 4.8% over the forecast period 2024 to 2031.

Key Takeaways

Key players operating in the Adoptive Cell Therapy are Broadcom, Celeno Communications, Infineon Technologies, Espressif Systems Shanghai Co Ltd, GCT Semiconductor Inc., I&C Technology, Intel Corporation, MediaTek, Inc., Microchip Technology Inc. The rising prevalence of cancer and strong product pipeline are fueling the demand for adoptive cell therapies. Major companies are focuses on strategic collaborations and acquisitions to strengthen their product portfolio and expand their global footprint.

Growing demand in the market is attributed to increase in research funding for clinical trials by both government as well as private organizations. In addition, favorable regulatory environment and approval of various CAR T-cell therapies have accelerated research and development activities.

Key companies are expanding their presence in developing regions such as Asia Pacific and Latin America owing to high untreated patient population and rising healthcare expenditure.

Market Drivers

Increase in incidence of cancer worldwide especially hematologic cancers such as leukemia and lymphoma is a key factor propelling the Adoptive Cell Therapy Market Growth. According to WHO, cancer burden is expected to grow to 27.5 million new cancer cases and 16.3 million cancer deaths by 2040. Additionally, advancements in genetic engineering techniques enabling development of novel therapy molecules are further augmenting the market demand. Growing awareness about advantages of targeted therapies along with strong product pipeline will continue to boost the adoptive cell therapy industry expansion over the forecast period.

The current geopolitical tensions are impacting the growth of the adoptive cell therapy market. Many countries are facing economic hardships and budget constraints due to rising inflation, supply chain issues and other economic challenges arising due to the pandemic and ongoing conflicts. This is limiting the investments in advanced healthcare technologies including adoptive cell therapies in various regions. However, certain countries are prioritizing healthcare even in difficult times to provide better treatment outcomes to patients.